Phase 1 N=32 Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults
Healthy
Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=8 Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…
Phase 1 N=56 A Study of LY110140 in Healthy Japanese Male Participants
Healthy Volunteer
Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants
Phase 1 N=24 Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
Hypoparathyroidism
Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)
Phase 1 N=56 A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
Healthy
Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants
Phase 1 N=24 Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants
Japanese Healthy Adult Male Participants
Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants
Phase 2 N=55 A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Influenza
Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants
Phase 1 N=48 This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects
Phase 2 N=48 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects
Spasmodic Torticollis
Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Phase 1 N=65 Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
Healthy
Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants
Phase 1 N=12 Phase I Study of GSK2982772 in Japanese Healthy Male Participants
Autoimmune Diseases
Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants
Phase 1 N=49 Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects
Healthy
Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants
Phase 1 N=18 A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
Healthy
Primary: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time [AUC(0-inf)] of Crizotinib — 1423; 3806; 6569 ng*hr/mL
Phase 1 N=40 V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
Staphylococcal Infection
Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio
Phase 1 N=72 Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Phase 4 N=160 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants
Phase 1 N=32 Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 1 N=82 TAK-114 Single- and Multiple-Dose Phase 1 Study
Clinical Pharmacology
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) — 0; 0; 1; 1 participants
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Phase 1 N=64 Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Number of Participants With Investigator Defined Drug-related Adverse Events — 2; 1; 4; 2 Participants
Phase 1 N=39 A Study of LY2484595 in Healthy Subjects
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter
Phase 1 N=52 Daprodustat Bioequivalence and Food Effect Study
Anaemia
Primary: Part 1:Area Under Plasma Concentration-time Curve (AUC) From Zero Hours to Last Measurable Concentration (AUC[0-t]) and AUC From Zero Hours Extrapolated to Infinity AUC…
Phase 1 N=24 Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants
Wilson Disease
Primary: Area Under The Plasma Concentration Versus Time Curve From Time 0 (Dosing) To The Last Quantifiable Concentration (AUCt) Of Plasma Total Molybdenum After Each Dose…
Phase 1 N=24 A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
Primary: Safety - Adverse Events — 1; 1; 0; 2 Participants
Phase 1 N=12 A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Phase 1 N=32 Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Congenital Bleeding Disorder · Healthy
Primary: Safety (Physical Examination, Vital Signs, ECG, Haematology, Biochemistry, Urinalysis, Coagulation Factors, Coagulation-related Parameters, Injection Site Tolerability…
Phase 1 N=27 A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=12 Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Hereditary Angioedema (HAE)
Primary: Peak Plasma Concentration (Cmax) of Icatibant and Metabolites — 1190; 340; 365 ng/mL
Phase 2 N=107 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275